ID: ALA4167842

Max Phase: Preclinical

Molecular Formula: C20H23Cl2N3O5

Molecular Weight: 456.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)[C@@H](C)NC(=O)c1ccc(NC(=O)c2[nH]c(C)c(Cl)c2Cl)c(OC(C)C)c1

Standard InChI:  InChI=1S/C20H23Cl2N3O5/c1-9(2)30-14-8-12(18(26)24-11(4)20(28)29-5)6-7-13(14)25-19(27)17-16(22)15(21)10(3)23-17/h6-9,11,23H,1-5H3,(H,24,26)(H,25,27)/t11-/m1/s1

Standard InChI Key:  KXBREHXIKYPCJV-LLVKDONJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 456.33

Molecular Weight (Monoisotopic): 455.1015

AlogP: 3.96

#Rotatable Bonds: 7

Polar Surface Area: 109.52

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.25

CX Basic pKa:

CX LogP: 3.36

CX LogD: 3.36

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.55

Np Likeness Score: -1.21

References

1. Durcik M, Lovison D, Skok Ž, Durante Cruz C, Tammela P, Tomašič T, Benedetto Tiz D, Draskovits G, Nyerges Á, Pál C, Ilaš J, Peterlin Mašič L, Kikelj D, Zidar N..  (2018)  New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,  154  [PMID:29778894] [10.1016/j.ejmech.2018.05.011]

2. Tiz DB,Skok Ž,Durcik M,Tomašič T,Mašič LP,Ilaš J,Zega A,Draskovits G,Révész T,Nyerges Á,Pál C,Cruz CD,Tammela P,Žigon D,Kikelj D,Zidar N.  (2019)  An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,  167  [PMID:30776691] [10.1016/j.ejmech.2019.02.004]

Source

Source(1):

• Scientific Literature